New external board appointment

Regulatory News Service

18 August 2016 13:00


Listing Rule LR 9.6.14 R (2)

Graham Chipchase, a Non-Executive Director of AstraZeneca PLC, has been appointed as Chief Executive Officer and a Director of Brambles Limited, a company listed on the Australian Securities Exchange, effective from 2017.

About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Respiratory and Autoimmunity, Cardiovascular and Metabolic Diseases, and Oncology. The Company is also active in inflammation, infection and neuroscience through numerous collaborations. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com    


CONTACTS

Media Enquiries

 

 

 

 

Neil Burrows

UK/Global

+44 203 749 5637

Vanessa Rhodes

UK/Global

+44 203 749 5736

Karen Birmingham

UK/Global

+44 203 749 5634

Rob Skelding

UK/Global

+44 203 749 5821

Jacob Lund

Sweden

+46 8 553 260 20

Michele Meixell

US

+1 302 885 2677

 

 

 

 

Investor Enquiries

 

 

     

UK

 

 

Thomas Kudsk Larsen

 

+44 203 749 5712

Craig Marks

Finance, Fixed Income, M&A

+44 7881 615 764

Nick Stone

Respiratory & Autoimmunity

+44 203 749 5716

Henry Wheeler

Oncology

+44 203 749 5797

Christer Gruvris

Infection & Neuroscience

+44 203 749 5711

 

 

 

 

US

 

 

Lindsey Trickett

Cardiovascular & Metabolic Diseases

+1 240 543 7970

Mitch Chan

Oncology

+1 240 477 3771

Dial / Toll-Free

 

+1 866 381 7277

 

Adrian Kemp
Company Secretary
AstraZeneca PLC

tags

  • Regulatory